Roche signs $370m deal for Phase I arthritis drug
Roche has committed hundreds of millions of dollars to an early-phase rheumatoid arthritis drug, a move that is indicative of big pharma's increasing tendency to license earlier phase compounds.
News & Analysis on the Clinical Development and Manufacture of Large Molecule Drugs